Filana Therapeutics, Inc. FLNA
Set alert
0.62 USD -0.04 -5.47%
At close · Oct 30
0.64 +0.02 +2.51%
After hours · Oct 30, 4:58 PM ET
0.62 Day range 0.6585
0.61 52-week range 3.39
- YTD
- -68.59%
- 1 year
- -81.04%
- Open
- 0.6585
- Prev close
- 0.658
- Mkt cap
- 30.05M
- Vol
- 215.57K
- Avg vol
- 2.02M
- EPS
- -0.87
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.62
- High
- 0.6585
3M chart
Signals (13)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 12, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 7, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 5, 2026 | 3 weeks ago |
| SMA: Bullish | Sep 29, 2026 | 1 month ago |
| SMA: Bullish | Sep 28, 2026 | 1 month ago |
| SMA: Bearish | Sep 24, 2026 | 1 month ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| SMA: Bullish | Sep 22, 2026 | 1 month ago |
| SMA: Bullish | Sep 22, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 22, 2026 | 1 month ago |
| RSI: Oversold | Sep 11, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 2, 2026 | 2 months ago |
| MACD: Buy Signal | Jul 31, 2026 | 3 months ago |
Financials — quick view
FLNA Revenue — quarterly 0
FLNA Net income — quarterly -8.60M
FLNA EPS — quarterly -0.18
News
- Filana Therapeutics Announces A Study Published By Yale Researchers Of New Preclinical Research On Simufilam Examined Simufilam's Impacts In Human Cell Line To Eliminate Tuberous Sclerosis Complex 2 Gene To Model Cellular Changes
- Filana Therapeutics Announces Publication in Cells of Promising Preclinical Findings for Simufilam in TSC2-Deficient Cells
- Filana Therapeutics to Participate in the 2026 Maxim Growth Summit
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- Positive FDA Decision Propels Rebranded Filana Therapeutics Epilepsy Research Forward
- Positive FDA Decision Propels Rebranded Filana Therapeutics Epilepsy Research Forward
- FDA Lifts Clinical Hold Form Filana Therapeutics' Investigational New Drug Application To Initiate Planned Phase 2a Trial In Participants With Tuberous Sclerosis Complex-Related Epilepsy
Your note
Sign in to keep a note on FLNA — it syncs with the Stock Master app.